PHC agrees the evaluation of its Innatus™ 3G peptide platform

Plant Health Care (AIM: PHC), a leading provider of novel patent-protected biological products to the global agriculture markets, recently announced that it has signed an agreement with a major industry player in the agricultural space regarding the evaluation of its Innatus™ 3G peptide platform. This technology platform enables the design, production and screening of a large pipeline of peptides with diverse biostimulant properties. The peptides can be used for both seed treatment and foliar applications.  They can also be combined with conventional crop protection chemicals, making them highly complementary to existing production practices.

Paul Schmidt, CEO of Plant Health Care, stated, "Over the past few months, we have been in active discussions with a number of major industry players that have the development and commercialization capabilities to exploit the full potential of our Innatus™ 3G peptide platform.  The response has been very positive and we are pleased to announce our first agreement arising from these discussions as we continue the dialogue with other major players."

While developing opportunities for its Innatus™ 3G peptide platform, Plant Health Care has continued to expand its research and development effort under the leadership of its Chief Scientific Officer, Dr. Zhongmin Wei. Over the past 18 months, the company added 4 research staff and, in 2015, plans to double its current researchpersonnel.  In addition, by mid-year, the company will relocate to a larger research facility in Seattle with over three times the square footage of its existing lab. The expanded workspace, staff increase, and planned addition of new growth chambers are expected to significantly accelerate the company's ability to develop new peptide families.